Related references
Note: Only part of the references are listed.Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19
Qirui Guo et al.
CELL HOST & MICROBE (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Immunological alternation in COVID-19 patients with cancer and its implications on mortality
Guangyao Cai et al.
ONCOIMMUNOLOGY (2021)
Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials
Laura Pasin et al.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2021)
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Nikolai Klebanov et al.
ONCOLOGIST (2021)
The nuclear export protein XPO1-from biology to targeted therapy
Asfar S. Azmi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana
Michael J. Lunski et al.
CANCER (2021)
Sex differences in COVID-19: the role of androgens in disease severity and progression
Mohamed S. Mohamed et al.
ENDOCRINE (2021)
The Risk and Prevalence of COVID-19 Infection in Colorectal Cancer Patients: a Systematic Review and Meta-analysis
Mohammad Hossein Antikchi et al.
JOURNAL OF GASTROINTESTINAL CANCER (2021)
Selinexor for the treatment of multiple myeloma
Klaus Podar et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
Qiurong Ruan et al.
INTENSIVE CARE MEDICINE (2020)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
Chih-Cheng Lai et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Peter Richardson et al.
LANCET (2020)
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Roujian Lu et al.
LANCET (2020)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Wenhua Liang et al.
LANCET ONCOLOGY (2020)
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection
Ana Pertejo-Fernandez et al.
LUNG CANCER (2020)
Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
Dan Pu et al.
MEDICINE (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan et al.
NATURE COMMUNICATIONS (2020)
COVID-19 Is Disproportionately High in African Americans. This Will Come as No Surprise...
Mona N. Fouad et al.
AMERICAN JOURNAL OF MEDICINE (2020)
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N=4532)
M. Montopoli et al.
ANNALS OF ONCOLOGY (2020)
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J. -M. Michot et al.
ANNALS OF ONCOLOGY (2020)
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
L. Zhang et al.
ANNALS OF ONCOLOGY (2020)
Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City
H. Miyashita et al.
ANNALS OF ONCOLOGY (2020)
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Daniel Blanco-Melo et al.
CELL (2020)
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
Carly G. K. Ziegler et al.
CELL (2020)
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Alba Grifoni et al.
CELL (2020)
Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients
Pierre Bost et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhuo Zhou et al.
CELL HOST & MICROBE (2020)
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Evangelos J. Giamarellos-Bourboulis et al.
CELL HOST & MICROBE (2020)
Functional exhaustion of antiviral lymphocytes in COVID-19 patients
Meijuan Zheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients
Hong-Yi Zheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
NKG2A and COVID-19: another brick in the wall
Luca Antonioli et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19
H. Hou et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
Toshio Hirano et al.
IMMUNITY (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
The many faces of the anti-COVID immune response
Santosha A. Vardhana et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
Yong Gao et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study
Dan Sun et al.
WORLD JOURNAL OF PEDIATRICS (2020)
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Hongzhou Lu
BIOSCIENCE TRENDS (2020)
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Jia Luo et al.
CANCER DISCOVERY (2020)
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta et al.
CANCER DISCOVERY (2020)
TMPRSS2 and COVID-19: serendipity or Opportunity for Intervention?
Konrad H. Stopsack et al.
CANCER DISCOVERY (2020)
Focus on the Crosstalk between COVID-19 and Urogenital Systems
Zhang-Song Wu et al.
JOURNAL OF UROLOGY (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Lennard Y. W. Lee et al.
LANCET (2020)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
SARS-CoV-2 and viral sepsis: observations and hypotheses
Hui Li et al.
LANCET (2020)
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
Kunyu Yang et al.
LANCET ONCOLOGY (2020)
Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
Alessandro Ceschi et al.
FRONTIERS IN PHARMACOLOGY (2020)
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Bo Diao et al.
FRONTIERS IN IMMUNOLOGY (2020)
Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury
Yingxia Liu et al.
NATIONAL SCIENCE REVIEW (2020)
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
Jing Yu et al.
JAMA ONCOLOGY (2020)
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Mingfeng Liao et al.
NATURE MEDICINE (2020)
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
Waradon Sungnak et al.
NATURE MEDICINE (2020)
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
Jian-Min Jin et al.
FRONTIERS IN PUBLIC HEALTH (2020)
African American children are at higher risk of COVID-19 infection
Sindhura Bandi et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2020)
Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation
Jiawei Chen et al.
AGING CELL (2020)
C5aR deficiency attenuates the breast cancer development via the p38/p21 axis
Jian Chen et al.
Aging-US (2020)
Type 1 interferons as a potential treatment against COVID-19
Erwan Sallard et al.
ANTIVIRAL RESEARCH (2020)
Lymphocyte Subset Counts inCOVID-19 Patients: A Meta-Analysis
Wei Huang et al.
CYTOMETRY PART A (2020)
Exportin 1 inhibition as antiviral therapy
Md Hafiz Uddin et al.
DRUG DISCOVERY TODAY (2020)
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
Dennis McGonagle et al.
AUTOIMMUNITY REVIEWS (2020)
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
Walter Fiedler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2020)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski et al.
SCIENCE IMMUNOLOGY (2020)
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19
Jeong Seok Lee et al.
SCIENCE IMMUNOLOGY (2020)
Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling
Benjamin Israelow et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19
Qing Ye et al.
JOURNAL OF INFECTION (2020)
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2020)
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
F. La Rosee et al.
LEUKEMIA (2020)
COVID-19 and Cancer: Current Challenges and Perspectives
Ziad Bakouny et al.
CANCER CELL (2020)
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19
Lars F. Westblade et al.
CANCER CELL (2020)
Cytokine Storms in Cancer and COVID-19
Casmir Turnquist et al.
CANCER CELL (2020)
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Carolina Lucas et al.
NATURE (2020)
A single-cell atlas of the peripheral immune response in patients with severe COVID-19
Aaron J. Wilk et al.
NATURE MEDICINE (2020)
Determinants of COVID-19 disease severity in patients with cancer
Elizabeth V. Robilotti et al.
NATURE MEDICINE (2020)
The CoV-2 outbreak: how hematologists could help to fight Covid-19
Sara Galimberti et al.
PHARMACOLOGICAL RESEARCH (2020)
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
Qinhai Ma et al.
PHARMACOLOGICAL RESEARCH (2020)
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Jerome Hadjadj et al.
SCIENCE (2020)
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
Chuang Guo et al.
NATURE COMMUNICATIONS (2020)
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
David J. Pinato et al.
CANCER DISCOVERY (2020)
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Jonathan A. C. Sterne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Lennard Y. W. Lee et al.
LANCET ONCOLOGY (2020)
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
Amir Hossein Mansourabadi et al.
LIFE SCIENCES (2020)
An inflammatory cytokine signature predicts COVID-19 severity and survival
Diane Marie Del Valle et al.
NATURE MEDICINE (2020)
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
Trent M. Woodruff et al.
TRENDS IN IMMUNOLOGY (2020)
Data regarding country-specific variability in Covid-19 prevalence, incidence, and case fatality rate
Larry E. Miller et al.
DATA IN BRIEF (2020)
Immunological features of coronavirus disease 2019 in patients with cancer
Marion Thibaudin et al.
EUROPEAN JOURNAL OF CANCER (2020)
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
Xuhan Zhang et al.
BLOOD ADVANCES (2020)
Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
Li Tan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer
Massimo Rugge et al.
NATURE CANCER (2020)
The immuno-oncological challenge of COVID-19
Lisa Derosa et al.
NATURE CANCER (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
Michael R. Cook et al.
JAMA ONCOLOGY (2019)
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Anna V. Tinker et al.
CLINICAL CANCER RESEARCH (2019)
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Rudragouda Channappanavar et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
Yu Wang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
Acalabrutinib and its use in treatment of chronic lymphocytic leukemia
Yasir Khan et al.
FUTURE ONCOLOGY (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace et al.
GUT (2018)
Repurposing of gamma interferon via inhalation delivery
Gerald C. Smaldone
ADVANCED DRUG DELIVERY REVIEWS (2018)
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis
Ming Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
The Dual Nature of Type I and Type II Interferons
Amanda J. Lee et al.
FRONTIERS IN IMMUNOLOGY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Christine Chen et al.
BLOOD (2018)
Immune checkpoint blockade in infectious diseases
Michelle N. Wykes et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Sylvia Heink et al.
NATURE IMMUNOLOGY (2017)
Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer
Marcela Moises Maluf Sanguinete et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group
Thomas S. Uldrick et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC
L. L. Bu et al.
JOURNAL OF DENTAL RESEARCH (2017)
Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
Ryota Tanaka et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
V. Atsaves et al.
LEUKEMIA (2017)
Severe cytokine release syndrome in a patient receiving PD-1-directed therapy
Seth J. Rotz et al.
PEDIATRIC BLOOD & CANCER (2017)
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
Rudragouda Channappanavar et al.
SEMINARS IN IMMUNOPATHOLOGY (2017)
Type I Interferon in Chronic Virus Infection and Cancer
Laura M. Snell et al.
TRENDS IN IMMUNOLOGY (2017)
Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Edward M. Behrens et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
Chunwan Lu et al.
ONCOIMMUNOLOGY (2017)
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications
Martina Musella et al.
ONCOIMMUNOLOGY (2017)
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Sang Taek Kim et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Prithviraj Bose et al.
BLOOD (2017)
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
Ramiro Garzon et al.
BLOOD (2017)
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model
Hu Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary
Nozomu Yanaihara et al.
MOLECULAR CARCINOGENESIS (2016)
Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice
Rudragouda Channappanavar et al.
CELL HOST & MICROBE (2016)
A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus
Naoki Tajiri et al.
CNS NEUROSCIENCE & THERAPEUTICS (2016)
Chronic Blockade of the Androgen Receptor Abolishes Age-Dependent Increases in Blood Pressure in Female Growth-Restricted Rats
John Henry Dasinger et al.
HYPERTENSION (2016)
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
Albiruni R. Abdul Razak et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Selective inhibition of autoimmune exacerbation while preserving the antitumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report
Marc Uemura et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Testosterone downregulates angiotensin II type-2 receptor via androgen receptor-mediated ERK1/2 MAP kinase pathway in rat aorta
Jay S. Mishra et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
Jian Gao et al.
ONCOLOGY REPORTS (2016)
Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection
Olivia Perwitasari et al.
PLOS ONE (2016)
Role of interleukin-6 in cancer progression and therapeutic resistance
Neeraj Kumari et al.
TUMOR BIOLOGY (2016)
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Biomarker development in the precision medicine era: lung cancer as a case study
Ashley J. Vargas et al.
NATURE REVIEWS CANCER (2016)
Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer
Freya A. Goumas et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma
Teppei Jinno et al.
ONCOLOGY REPORTS (2015)
Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
Tomofumi Miura et al.
PANCREAS (2015)
Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy
Steven E. Bosinger et al.
CURRENT HIV/AIDS REPORTS (2015)
Targeting heat shock proteins in metastatic castration-resistant prostate cancer
Arun A. Azad et al.
NATURE REVIEWS UROLOGY (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells
Ammad Ahmad Farooqi et al.
CANCER CELL INTERNATIONAL (2014)
Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2: ERG-Positive Prostate Cancer
Sun Yoo et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche
Surya Kumari Vadrevu et al.
CANCER RESEARCH (2014)
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer
Lanxi Song et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
Jared M. Lucas et al.
CANCER DISCOVERY (2014)
The role of intratumoral and systemic IL-6 in breast cancer
Christine Dethlefsen et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
Chin Hao Chang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes
Abdul M. Mondal et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG
Andreas Pettersson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium
Stephanie Bertram et al.
JOURNAL OF VIROLOGY (2013)
IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
Miao-Fen Chen et al.
MOLECULAR CANCER (2013)
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
J. Etchin et al.
LEUKEMIA (2013)
The role of IL-6 in the radiation response of prostate cancer
Chun-Te Wu et al.
RADIATION ONCOLOGY (2013)
Viral Subversion of the Nuclear Pore Complex
Valerie Le Sage et al.
VIRUSES-BASEL (2013)
Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice
Bastian Hatesuer et al.
PLOS PATHOGENS (2013)
The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
Qing Chang et al.
NEOPLASIA (2013)
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
Rosa Lapalombella et al.
BLOOD (2012)
Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
Zoran Culig et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts
Stephanie Bertram et al.
PLOS ONE (2012)
Genome-wide DNA Methylation Events in TMPRSS2-ERG Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with miR-26a Hypermethylation
Stefan T. Boerno et al.
CANCER DISCOVERY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
Marina Lesina et al.
CANCER CELL (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Effects of Siltuximab on the IL-6-Induced Signaling Pathway in Ovarian Cancer
Yuqi Guo et al.
CLINICAL CANCER RESEARCH (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Androgen receptor and androgen-dependent gene expression in lung
Laura Mikkonen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
Sergei Grivennikov et al.
CANCER CELL (2009)
Nosocomial infections in patients with cancer
Mini Kamboj et al.
LANCET ONCOLOGY (2009)
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
N. J. Sullivan et al.
ONCOGENE (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection
Valentina Cecchinato et al.
JOURNAL OF IMMUNOLOGY (2008)
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma
J. M. Lucas et al.
JOURNAL OF PATHOLOGY (2008)
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland
Pasquale Sansone et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Sizhi Paul Gao et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
Qianben Wang et al.
MOLECULAR CELL (2007)
Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction
Michelle D'Souza et al.
JOURNAL OF IMMUNOLOGY (2007)
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate
J. Clark et al.
ONCOGENE (2007)
Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion
H-H Yeh et al.
ONCOGENE (2006)
Phenotypic analysis of mice lacking the Tmprss2-encoded protease
TS Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Nuclear targeting of adenovirus type 2 requires CRM1-mediated nuclear export
S Strunze et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Serum interleukin-6 levels reflect the disease status of colorectal cancer
YC Chung et al.
JOURNAL OF SURGICAL ONCOLOGY (2003)
Mechanism of antiandrogen action:: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor
V Georget et al.
BIOCHEMISTRY (2002)